Jpmorgan Chase & CO Avita Medical, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Avita Medical, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 32,344 shares of RCEL stock, worth $416,267. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,344
Previous 23,359
38.46%
Holding current value
$416,267
Previous $185,000
87.03%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding RCEL
# of Institutions
72Shares Held
5.96MCall Options Held
35.5KPut Options Held
38K-
Black Rock Inc. New York, NY1.78MShares$23 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.42MShares$18.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA594KShares$7.65 Million0.0% of portfolio
-
State Street Corp Boston, MA520KShares$6.69 Million0.0% of portfolio
-
Essex Investment Management CO LLC Boston, MA231KShares$2.97 Million0.46% of portfolio
About AVITA Medical, Inc.
- Ticker RCEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 25,030,900
- Market Cap $322M
- Description
- AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and prop...